Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Higher glycemic time in range may benefit T2D patients

Publish date:: September 28, 2020

Key clinical point: Targeting increased glycemic time-in-range may improve clinical outcomes in patients with type 2 diabetes.

Major finding: A 10% rise in average time in glycemic range linked with a 6% cut in major adverse cardiac events and a 10% drop in severe hypoglycemic events.

Study details: Post hoc analysis of data from 5,774 patients from the DEVOTE trial.

Disclosures: DEVOTE was funded by Novo Nordisk. Dr. Bergenstal has had financial relationships with Novo Nordisk and several other companies.

Citation:

Bergenstal R et al. EASD 2020, Abstract 159.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Cardiology

Sac/val heart failure benefit extends to diabetes patients,

Sedentary postmenopausal women have higher heart failure risk,

Experts disagree with USPSTF’s take on pediatric blood pressure screening,

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit,

Don’t miss cardiovascular risk factors in transgender patients,